^
    almost2years
    Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study (IASLC-WCLC 2022)
    Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations. And further investigate is warranted to confirm this new chemo-free strategy.
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719A • EGFR G709T
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    2years
    Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study (ELCC 2022)
    Conclusions Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations. And further investigate is warranted to confirm this new chemo-free strategy.
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719A • EGFR G709T
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)